Science AI Journal
Immunology and Microbiology · Research topic

Open research questions in Immune Cell Function and Interaction

644 gap statements mined from Immune Cell Function and Interaction papers in our 7.9M-paper local library, which holds 2,439 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Immune Cell Function and Interaction? See the ranked Medicine journals.

What the literature leaves open

  • The current treatments for ovarian cancer have limitations and challenges. There is a need for novel therapeutic strategies to improve treatment outcomes. The paper identifies the potential of natural killer cells as a gap in current research.

    Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations · 2026 · DOI

  • The study notes that cancer is now classified by both histological and molecular subtypes, making it challenging to interpret the results. The analysis of LNK mRNA expression and protein localization requires specialized techniques and instruments. The study highlights the need for independent validation of the findings due to the exploratory nature of the analysis.

    LNK expression, subcellular localisation and survival associations in breast, cervical and colorectal cancer · 2026 · DOI

  • The study requires the isolation and characterization of adaptive NK cells from breast tumor tissue. The functional properties of adaptive NK cells in the breast tumor microenvironment need to be investigated.

    Characterization and ex vivo functional properties of NKG2C+ NK cells with adaptive features in breast tumors · 2026 · DOI

  • The lack of understanding of the role of Schwann cells in the tumor immune microenvironment. The need to elucidate the mechanisms underlying Schwann cell-mediated immune evasion. The requirement for therapeutic strategies targeting Schwann cells.

    The Emerging Role of Schwann Cells in the Tumor Immune Microenvironment and Its Potential Clinical Application · 2024 · DOI

  • Despite their abundance, the mechanisms governing their proliferative state remain poorly understood.

    Alternative splicing of CD244 restrains natural killer cells at the maternal-fetal interface · 2026 · DOI

  • While NK cells are extensively studied in infections, transplants, and cancer, their role in cardiovascular pathophysiology remains incompletely defined.

    Natural killer cells in the heart: determinants of their protective-to-pathogenic transition and therapeutic implications · 2026 · DOI

  • While NK cell memory holds promise for infection control, its role in bacterial infections remains poorly understood.

    NK cells undergo transcriptional and functional reprogramming following Streptococcus pneumoniae infection · 2025 · DOI

  • Recombinant poxviruses have been extensively studied as vaccine vectors, yet the specific mechanisms by which they engage the immune system remain incompletely understood.

    Poxvirus Vectors Activate Human NK and MAIT Cells in a Type I Interferon, IL‐18, and Monocyte‐Dependent Manner · 2025 · DOI

  • Expression of HLA-C and HLA-E was lacking or low, insufficient to trigger reporter cells expressing the inhibitory receptors KIR2DL1, -2DL2, or -2DL3.

    NK-cell cytotoxicity toward pluripotent stem cells and their neural progeny: impacts of activating and inhibitory receptors and KIR/HLA mismatch · 2024 · DOI

  • Although the full functional niche of CD89 + NK cells remains unexplored, these intriguing data suggest the CD89 axis could represent a novel immunotherapeutic target in the mucosae or early life.

    FcαRI (CD89) is upregulated on subsets of mucosal and circulating NK cells and regulates IgA-class specific signaling and functions · 2024 · DOI

  • The role of ieILC1-like NK cells in modulating clinical responses to immune checkpoint blockade warrants investigation.

    Intraepithelial ILC1‐Like NK Cells Increase Lymphocyte Infiltration into the Tumor Microenvironment via the CXCL10 Axis · 2024 · DOI

  • However, the antitumor effects and genes involved in the direct promotion of NK cell‐mediated activation using Elo in CD16‐independent NK cells are not clearly known.

    Elotuzumab Enhances CD16‐Independent NK Cell‐Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell‐Enhancing Genes · 2024 · DOI

  • However, their specificity and independent prognostic value relative to established aging biomarkers remain to be rigorously validated in longitudinal human studies.

    Natural killer cells: gatekeepers of healthy aging in longevity medicine · 2026 · DOI

  • Limited understanding of the key cellular correlates of ICB responsiveness in tsMHC-I impaired tumours. Need for novel therapeutic strategies to enhance ICB responsiveness in tsMHC-I impaired models.

    Reinvigorating COTL1high NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours · 2026 · DOI

  • The underlying mechanisms enabling immunotherapy responsiveness in tsMHC-I impaired tumours remain poorly understood. The key cellular correlates of ICB responsiveness in tsMHC-I impaired tumours are not well defined.

    Reinvigorating COTL1high NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours · 2026 · DOI

  • Many cancer immunotherapies rely on antigen-specific T-cell priming and cannot overcome tumor heterogeneity and patient variability. Therapies that activate the innate immune response, particularly natural killer cells, are needed to address this gap.

    Biomimetic virus-like mesoporous silica nanoparticles activate NK cells indirectly via monocyte crosstalk · 2026 · DOI

  • There is a scarcity of published literature on pre-clinical and clinical meta-analyses in the context of CAR-NK therapy. A recent meta-analysis provided insights into the preclinical efficacy of CAR-NK in hematologic malignancies, where similar findings emerged as CAR-NK therapy showed statistically significant overall benefit in improving tumor and survival outcomes.

    Evaluation of Efficacy and Safety of Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cells in Breast Cancer: A Systematic Review and Meta-Analysis · 2026 · DOI

  • However, the specific role of the IgA receptor cluster of differentiation (CD)89, expressed by a subset of natural killer (NK) cells, is poorly explored.

    FcαRI (CD89) is upregulated on subsets of mucosal and circulating NK cells and regulates IgA-class specific signaling and functions · 2024 · DOI

  • The conclusion may be limited as only one TCR from both the CD8 and CD4 subsets was tested. The strong species restriction of MHC class I may limit the direct priming of human tumor antigen-specific CTLs by murine APCs.

    Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and α-galactosylceramide-pulsed antigen-presenting cells · 2026 · DOI

  • The activation of iPSC-iNKT cells by glycolipid ligands remains a critical step for iNKT cell-mediated cancer therapy. The production of iNKT cells from patients with cancer is challenging.

    Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and α-galactosylceramide-pulsed antigen-presenting cells · 2026 · DOI

  • The development of bispecific or multispecific CAR-NK cells that can recognise multiple tumour antigens at the same time, - Optimising the in vivo expansion technology of NK cells, - The study of novel cytokine combinations, gene editing technology and other means to enhance the proliferation ability and survival time of NK cells, - The application of artificial intelligence technology in NK cell therapy…

    Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations · 2026 · DOI

  • The study utilized publicly available datasets and did not include new experimental data, - The analysis was limited to the datasets available on the GEPIA and cBioPortal platforms, - The study did not investigate the mechanisms underlying the observed associations between LNK expression…

    LNK expression, subcellular localisation and survival associations in breast, cervical and colorectal cancer · 2026 · DOI

  • Resistance to immune-checkpoint blockade remains common, - clinical efficacy of NKG2A blockade has not been established, - the phase II MIMOSA study had a small, single-arm cohort, - cross-tumor findings should not be treated as breast cancer efficacy…

    The HLA-E–NKG2A axis in breast cancer: an emerging NK-cell checkpoint and therapeutic target · 2026 · DOI

  • Evaluating breast cancer-specific and cross-tumor evidence, - assessing the NKG2A/NKG2C balance, - developing therapeutic combinations, - practical biomarker…

    The HLA-E–NKG2A axis in breast cancer: an emerging NK-cell checkpoint and therapeutic target · 2026 · DOI

  • Future research should focus on elucidating the mechanisms underlying the crosstalk between SCs and NK cells within…

    The Emerging Role of Schwann Cells in the Tumor Immune Microenvironment and Its Potential Clinical Application · 2024 · DOI

Most-cited papers in Immune Cell Function and Interaction

Most recent work

Find a gap in your own Immune Cell Function and Interaction sub-topic

This page shows what the Immune Cell Function and Interaction literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Immunology and Microbiology

Immune cells in cancer
1,090 open questions
Vector-borne infectious diseases
916 open questions
Antibiotic Use and Resistance
880 open questions
interferon and immune responses
771 open questions
Aquaculture disease management and microbiota
766 open questions
HIV Research and Treatment
730 open questions
Psoriasis: Treatment and Pathogenesis
696 open questions
Immunotherapy and Immune Responses
614 open questions
Open questions raised by papers listed on this page include: (1) There is a need for novel therapeutic strategies to improve treatment outcomes (“Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and…”, 2026); (2) Despite their abundance, the mechanisms governing their proliferative state remain poorly understood (“Alternative splicing of CD244 restrains natural killer cells at the…”, 2026); (3) Their specificity and independent prognostic value relative to established aging biomarkers remain to be rigorously validated in longitudinal human studies (“Natural killer cells: gatekeepers of healthy aging in longevity medicine”, 2026); (4) The underlying mechanisms enabling immunotherapy responsiveness in tsMHC-I impaired tumours remain poorly understood (“Reinvigorating COTL1high NK cells via GITR signalling overcomes immune…”, 2026); (5) Therapies that activate the innate immune response, particularly natural killer cells, are needed to address this gap (“Biomimetic virus-like mesoporous silica nanoparticles activate NK cells…”, 2026). 644 gap statements have been mined from Immune Cell Function and Interaction papers in our 7.9M-paper local library, which holds 2,439 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.